The U.S. Food and Drug Administration has granted fast-track designation to a new therapy for aggressive ovarian, fallopian tube, and peritoneal cancer, according to Targeted Oncology. Developed by the Chinese firm RemeGen, RC88 is designed for patients with treatment-resistant cancers and poor prognoses. Phase 2 clinical trials are slated to begin soon.
Related Posts
Terms of endearment: Can’t wait to see you, lamb chop.
What is your favorite term of endearment for your spouse? Chances are it is honey, unless you want a favor and it escalates to sweetheart or sweetie. But…
New Alzheimer’s drug adjustments
Biogen has updated its prescribing guidelines for its controversial Alzheimer’s drug. The updated guidelines for the drug Aduhelm say the drug should be…
Kevlar isn’t just for vests
Medical technology has developed dramatically in recent decades, but up until now there hasn’t been a suitable replacement for human cartilage. According…